Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Sanaa Reports: Yemen's Houthi forces claimed on the 27th that the group launched a drone strike on facilities transporting crude oil from eastern Saudi Arabia to Yanbu port on the Red Sea, stating that this was a response to Saudi drones "violating Yemeni airspace." (Xinhua News Agency)

Sanaa Reports: Yemen's Houthi forces claimed on the 27th that the group launched a drone strike on facilities transporting crude oil from eastern Saudi Arabia to Yanbu port on the Red Sea, stating that this was a response to Saudi drones "violating Yemeni airspace." (Xinhua News Agency)

智通财经智通财经2026/07/27 16:31
Show original
Sana'a News: On the 27th, Yemen's Houthi forces stated that they launched a drone strike against facilities involved in transporting crude oil from eastern Saudi Arabia to Yanbu Port on the Red Sea, claiming this was in response to Saudi drones "violating Yemeni airspace." (Xinhua News Agency)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds